Key insights
- Actinium Pharmaceuticals will present preclinical data on ATNM-400 (solid tumors) and Actimab-A (leukemia) at the AACR meeting. While the company has a strong current ratio and cash position, the stock trades near its 52-week low. The news itself is unlikely to move the broader market, but negative trial outcomes could pressure the stock.
NEW YORK - Actinium Pharmaceuticals (NYSE American:ATNM) will present two research abstracts at the American Association for Cancer Research Annual Meeting 2026 in San Diego, California, according to a press release statement. The company’s stock currently trades at $0.98, near its 52-week low of $0.95, despite a market capitalization of $30.6 million.
The company announced that both presentations will occur on April 21 during the session Radiopharmaceutical Platforms for Theranostic Precision Oncology. The presentations will take place from 2:00 PM to 5:00 PM PT.
One poster will feature previously undisclosed preclinical data on ATNM-400, an Ac-225 radioconjugate being developed for solid tumors. The data will demonstrate activity across multiple solid tumor models. ATNM-400 targets an antigen distinct from PSMA and has shown preclinical activity in metastatic castration-resistant prostate cancer, non-small cell lung cancer, and breast cancer.
The second poster will present data on Actimab-A, which the company is developing for acute myeloid leukemia and myelodysplastic syndrome. The presentation will include information on what the company describes as a mechanism of transcriptional reprogramming. While Actinium maintains a strong current ratio of 6.2 and holds more cash than debt on its balance sheet, InvestingPro analysis suggests the stock is undervalued at current levels, with 12 additional ProTips available to subscribers on the platform.
Actimab-A is being developed in collaboration with the National Cancer Institute and is advancing toward a Phase 2/3 trial. The therapy has shown improved survival in relapsed/refractory AML when combined with CLAG-M therapy.
The ATNM-400 poster will be numbered 5824 and displayed at Poster Section 16, Board #18. The Actimab-A poster will be numbered 5827 and displayed at Poster Section 16, Board #21.
Actinium Pharmaceuticals develops targeted radiotherapies for cancer treatment. The company holds approximately 250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.